Nanae Takatori, MD
Internal Medicine · San Diego
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Sharp Rees-Stealy Medical Group Inc · 872 clinicians in this group
Looking this up.
Hospitals listed: Sharp Memorial Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Takatori’s office at (858) 499-2600 to ask if they take your plan before you enroll.
California Medical Board record
Licence A126593 · Current
Licensed to practise in California · since 2013 · expires 2027-07-31 · David Geffen School of Medicine at UCLA.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 73.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Sharp Memorial HospitalSan Diego, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sharp Healthcare, which runs 6 hospitalsPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.41 (0.88 to 1.95) · 7,340 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.498, Oct 2024 – Sep 2025
See every measure and the patient survey for Sharp Memorial Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.41 (0.88 to 1.95) · 7,340 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.498 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.2 (0.34 to 2.06) · 1,904 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.19 (0.93 to 1.46) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 168.64 (124.64 to 212.63) · 111 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 139 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 149 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 451 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.2 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 5,777 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.11 to 0.48) · 9,499 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.11 to 0.47) · 9,575 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.81 (1.02 to 4.61) · 2,561 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.15 (0 to 2.59) · 923 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (0.72 to 3.28) · 2,373 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.93 (5.57 to 16.3) · 974 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.33 (1.15 to 7.5) · 963 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.12 to 2.99) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 111 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.591 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.732 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.162 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.349 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.495 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.2 · 346 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.5 · 992 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9.7 · 532 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6.6 · 584 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 995 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.2 (4.3 to 9) · 135 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (9.3 to 16.5) · 135 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.4 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.8 · 61 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 263 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (10.2 to 17.2) · 1,001 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 636 cases | No different | Jan 2024 – Dec 2024 |
What patients said (5,623 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$45,607
Medicare paid this office $45,607 for 127 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 41 | $17,516 | $417 |
| Biopsy of large bowel using a flexible endoscope | 33 | $7,684 | $233 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 76 | $4,206 | $55 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $4,148 | $259 |
| Return visit (30+ min) | 19 | $2,515 | $105 |
See all 10 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 41 | $17,516 | $417 |
| Biopsy of large bowel using a flexible endoscope | 33 | $7,684 | $233 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 76 | $4,206 | $55 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $4,148 | $259 |
| Return visit (30+ min) | 19 | $2,515 | $105 |
| New patient visit (45+ min) | 11 | $1,553 | $141 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 60 | $786 | $11 |
| Short return visit (20+ min) | 12 | $757 | $63 |
| Injection, fentanyl citrate, 0.1 mg | 62 | $42 | None |
| Injection, midazolam hydrochloride, per 1 mg | 76 | $35 | None |
Procedures Medicare counted
| Colonoscopy | 76 | More than 73% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 28 | More than 55% of doctors who do this |
Who their Medicare patients are
127 Original Medicare patients in 2024. Average age 72 · Women 62% · Also on Medicaid 13% · Health risk score 1.26. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 61% · Coronary heart disease 27% · Chronic kidney disease 25% · Depression 24% · Diabetes 22% · Atrial fibrillation 18% · Heart failure 16% · Cancer 16% · COPD 11%.
The office billed $223,652, Medicare allowed $56,083 and paid $45,607; for 786 services of 29 kinds; $77 of it was for drugs given in the office and $45,530 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 127 | 786 | 72 | 1.26 | $223,652 | $45,607 |
| 2023 | 163 | 1,128 | 71 | 1.29 | $329,395 | $62,273 |
| 2022 | 158 | 1,090 | 73 | 1.22 | $300,057 | $60,593 |
| 2021 | 139 | 1,058 | 72 | 1.41 | $276,868 | $54,608 |
| 2020 | 120 | 791 | 71 | 1.76 | $185,614 | $40,887 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 56 | $24,357 | $427 |
| Biopsy of large bowel using a flexible endoscope | 52 | $8,814 | $166 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $7,795 | $278 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 99 | $5,449 | $54 |
| Telephone medical discussion with physician, 11-20 minutes | 24 | $2,396 | $77 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,313 | $109 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 79 | $1,096 | $11 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $613 | $41 |
| Injection, fentanyl citrate, 0.1 mg | 99 | $68 | None |
| Injection, midazolam hydrochloride, per 1 mg | 99 | $60 | None |
2022: 10 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 37 | $15,851 | $406 |
| Biopsy of large bowel using a flexible endoscope | 47 | $11,823 | $252 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $7,388 | $321 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 96 | $5,487 | $53 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $2,354 | $71 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $2,074 | $104 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,456 | $112 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 75 | $989 | $10 |
| Injection, fentanyl citrate, 0.1 mg | 92 | $56 | None |
| Injection, midazolam hydrochloride, per 1 mg | 95 | $52 | None |
2021: 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 36 | $14,988 | $416 |
| Biopsy of large bowel using a flexible endoscope | 46 | $9,647 | $210 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $5,081 | $267 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 87 | $4,861 | $54 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $1,963 | $73 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,715 | $101 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,590 | $114 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 67 | $1,069 | $10 |
| Bacterial culture for aerobic isolates | 11 | $89 | $8 |
| Injection, fentanyl citrate, 0.1 mg | 84 | $43 | None |
| Injection, midazolam hydrochloride, per 1 mg | 85 | $41 | None |
2020: 11 services
| Biopsy of large bowel using a flexible endoscope | 32 | $9,729 | $295 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $6,360 | $277 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $5,080 | $363 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 62 | $3,383 | $51 |
| Telephone medical discussion with physician, 11-20 minutes | 32 | $2,467 | $65 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,405 | $94 |
| Return visit (30+ min) | 15 | $1,353 | $80 |
| Telephone medical discussion with physician, 5-10 minutes | 17 | $788 | $39 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 44 | $613 | $9 |
| Injection, fentanyl citrate, 0.1 mg | 61 | $44 | None |
| Injection, midazolam hydrochloride, per 1 mg | 61 | $30 | None |
Drugs they prescribed that Part D paid
$403,256
Pharmacies billed $403,256 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 404) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
301 generic and 103 brand-name prescriptions · $403,256 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Creon | 11 | $21,032 | $1,912 |
| Linzess | 27 | $20,483 | $759 |
| Entecavir | 13 | $9,529 | $733 |
| Ursodiol | 31 | $7,281 | $235 |
| Trulance | 12 | $6,805 | $567 |
See all 8 drugs
| Creon | 11 | $21,032 | $1,912 |
| Linzess | 27 | $20,483 | $759 |
| Entecavir | 13 | $9,529 | $733 |
| Ursodiol | 31 | $7,281 | $235 |
| Trulance | 12 | $6,805 | $567 |
| Omeprazole | 88 | $1,761 | $20 |
| Cholestyramine | 15 | $763 | $51 |
| Pantoprazole | 28 | $419 | $15 |
Year by year
| 2024 | 404 | 117 | 0% (0) | 25% | $403,256 |
| 2023 | 382 | 144 | 0% (0) | 23% | $226,918 |
| 2022 | 345 | 122 | None | 26% | $97,851 |
| 2021 | 402 | 127 | 0% (0) | None | $168,393 |
| 2020 | 361 | 138 | 0% (0) | 21% | $111,124 |
| 2019 | 436 | 179 | None | 15% | $62,714 |
| 2018 | 188 | 107 | 0% (0) | 24% | $35,289 |
| 2017 | 64 | 28 | 0% (0) | 64% | $10,758 |
| 2016 | 46 | 13 | 0% (0) | 41% | $6,876 |
| 2015 | 34 | 13 | 38% (13) | None | $1,376 |
| 2014 | 20 | None | None | None | $1,156 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Linzess | 32 | $22,850 | $714 |
| Trulance | 16 | $10,517 | $657 |
| Ursodiol | 18 | $7,381 | $410 |
| Budesonide Ec | 13 | $4,258 | $328 |
| Sucralfate | 11 | $4,220 | $384 |
| Cholestyramine | 17 | $1,517 | $89 |
| Sod Sulf-Potass Sulf-Mag Sulf | 14 | $1,165 | $83 |
| Omeprazole | 68 | $1,109 | $16 |
| Pantoprazole | 35 | $845 | $24 |
| Gavilyte-G | 23 | $366 | $16 |
| Famotidine | 16 | $157 | $10 |
2022: 10 drugs
| Linzess | 25 | $16,605 | $664 |
| Lubiprostone | 12 | $7,424 | $619 |
| Ursodiol | 16 | $6,779 | $424 |
| Trulance | 12 | $6,525 | $544 |
| Motegrity | 11 | $5,205 | $473 |
| Cholestyramine | 16 | $1,697 | $106 |
| Omeprazole | 72 | $1,266 | $18 |
| Pantoprazole | 38 | $905 | $24 |
| Propranolol | 14 | $418 | $30 |
| Gavilyte-G | 12 | $211 | $18 |
2021: 9 drugs
| Sucralfate | 22 | $9,682 | $440 |
| Linzess | 15 | $8,448 | $563 |
| Lubiprostone | 13 | $8,000 | $615 |
| Movantik | 15 | $6,642 | $443 |
| Ursodiol | 11 | $6,216 | $565 |
| Omeprazole | 103 | $2,147 | $21 |
| Suprep | 14 | $1,556 | $111 |
| Pantoprazole | 51 | $1,498 | $29 |
| Propranolol | 14 | $457 | $33 |
2020: 5 drugs
| Linzess | 29 | $19,210 | $662 |
| Omeprazole | 101 | $2,253 | $22 |
| Pantoprazole | 42 | $1,292 | $31 |
| Lactulose | 13 | $663 | $51 |
| Gavilyte-G | 18 | $222 | $12 |
2019: 9 drugs
| Lialda | 19 | $13,674 | $720 |
| Mesalamine | 11 | $7,874 | $716 |
| Gavilyte-C | 86 | $3,075 | $36 |
| Budesonide Ec | 14 | $1,648 | $118 |
| Omeprazole | 93 | $1,500 | $16 |
| Pantoprazole | 20 | $384 | $19 |
| Ondansetron Odt | 42 | $346 | $8 |
| Dicyclomine | 13 | $283 | $22 |
| Metronidazole | 11 | $98 | $9 |
2018: 5 drugs
| Creon | 11 | $11,517 | $1,047 |
| Gavilyte-C | 58 | $2,079 | $36 |
| Ondansetron | 11 | $272 | $25 |
| Dicyclomine | 15 | $234 | $16 |
| Omeprazole | 12 | $189 | $16 |
2015: 1 drug
| Metoprolol | 11 | $494 | $45 |
2014: 1 drug
| Metoprolol | 12 | $576 | $48 |
Money from drug and device companies
$141 in 2024
| 2024 | 1 | 1 | None | $141 |
| 2022 | 1 | 1 | None | $125 |
| 2021 | 1 | 1 | None | $93 |
| 2020 | 1 | 1 | None | $108 |
| 2019 | 1 | 1 | None | $116 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Olympus America | Single Use Electrosurgical Knife Kd-655 | $141 | 1 payment
|
See the published payment
| Olympus America | Meals · 2024-11-07 | Single Use Electrosurgical Knife Kd-655 | $141 |
See earlier years (2022, 2021, 2020, 2019)
2022: $125
| Abbvie | Rinvoq | $125 | 1 payment
|
2021: $93
| AbbVie | None | $93 | 1 payment
|
2020: $108
| Janssen Scientific Affairs | Stelara | $108 | 1 payment
|
2019: $116
| Intercept Pharmaceuticals | Ocaliva | $116 | 1 payment
|
Professional record
- NPI
- 1508123217
- Licence
- CA A126593California A126593: Current · expires 2027-07-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 2929 Health Center Dr, San Diego, CA, 92123
- NPI first listed
- 2012-04-19
- NPI last updated
- 2019-12-16
- NPI record certified
- 2019-12-16
This is when the NPI record was last certified, not a medical board exam.